Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-706 in advanced solid tumors
NCT06533605Phase 1Not yet recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Aug 2024
- Primary completion
- Jul 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of SSGJ-706 in solid tumor (12 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoints: Dose Limiting Toxicities at 12 months and Maximum Tolerated Dose or Maximum Administered Dose at 12 months. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
SSGJ-706
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06533605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06533605.